Formulation and evaluation of mefenamic acid emulgel for topical delivery  by Khullar, Rachit et al.
Saudi Pharmaceutical Journal (2012) 20, 63–67King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEFormulation and evaluation of mefenamic acid emulgel
for topical deliveryRachit Khullar *, Deepinder Kumar, Nimrata Seth, Seema SainiDepartment of Pharmaceutics, Rayat Institute of Pharmacy, Railmajra, Punjab, IndiaReceived 27 June 2011; accepted 11 August 2011











19-0164 ª 2011 King Saud
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.jsps.2011.08.001





osting by EAbstract Emulgels have emerged as a promising drug delivery system for the delivery of hydro-
phobic drugs. The objective of the study was to prepare emulgel of mefenamic acid, a NSAID, using
Carbapol 940 as a gelling agent. Mentha oil and clove oil were used as penetration enhancers. The
emulsion was prepared and it was incorporated in gel base. The formulations were evaluated for
rheological studies, spreading coefﬁcient studies, bioadhesion strength, skin irritation studies,
in vitro release, ex vivo release studies, anti-inﬂammatory activity and analgesic activity. Formula-
tion F2 and F4 showed comparable analgesic and anti-inﬂammatory activity when they compared
with marketed diclofenac sodium gel. So, it can be concluded that topical emulgel of mefenamic
acid posses an effective anti-inﬂammatory and analgesic activity.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Several analgesic preparations are available in the market as
different topical preparations. Mefenamic acid, an effective
NSAID has always been used as an anti-inﬂammatory and
analgesic agent. Conventionally it is available in the form of
tablets and suspensions. There is no marketed topical formula-
tion of mefenamic acid available till date. Most of the topical76338345.
hoo.co.in (R. Khullar).
y. Production and hosting by
Saud University.
lsevierpreparations are used for the localized effects at the site of
their application by virtue of drug penetration into the under-
lying layers of skin or mucous membranes (Lionberger and
Brennan, 2010). Although some unintended drug absorption
may occur, it is of sub therapeutic quantities and generally
of minor concern. Gels are a relatively newer class of dosage
form created by entrapment of large amounts of aqueous or
hydroalcoholic liquid in a network of colloidal solid particles,
which may consist of inorganic substances, such as aluminum
salts or organic polymers of natural or synthetic origin
(Kumar and Verma, 2010). They have a higher aqueous com-
ponent that permits greater dissolution of drugs, and also per-
mit easy migration of the drug through a vehicle that is
essentially a liquid, compared with the ointment or cream base
(Gennaro, 1995; Ansel et al., 1999). These are superior in terms
of use and patient acceptability. In spite of many advantages of
gels a major limitation is in the delivery of hydrophobic drugs.
So to overcome this limitation, emulgels are prepared and used
so that even a hydrophobic therapeutic moiety can enjoy the
unique properties of gels (Topical Emulsion, 2004). When gels
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referred as EMULGELS (Mohamed, 2004). In recent years,
there has been great interest in the use of novel polymers with
complex functions as emulsiﬁers and thickeners because the
gelling capacity of these compounds allows the formulation
of stable emulsions and creams by decreasing surface and
interfacial tension and at the same time increasing the viscosity
of the aqueous phase (Gupta et al., 2010). Emulgels for derma-
tological use have several favorable properties such as being
thixotropic, greaseless, easily spreadable, easily removable,
emollient, nonstaining, long shelf life, bio-friendly, transparent
and pleasing appearance (Stanos, 2007).
The aim of this work was to develop an emulgel formula-
tion of mefenamic acid, a hydrophobic drug, using Carbopol
940 as gelling agent and two types of penetration enhancer,
i.e., Clove oil and Mentha oil. The inﬂuence of gelling agent
and penetration enhancers was investigated. The rheological
studies, spreading coefﬁcient studies, bioadhesion strength,
skin irritation studies, in vitro release, ex vivo release studies,
anti-inﬂammatory activity and analgesic activity of the pre-
pared emulgels were also evaluated.
2. Materials and methods
2.1. Materials
Mefenamic acid was obtained as a gift sample from Lexicon
Biotech Pvt. Ltd. Baddi (Himachal Pradesh), Carbopol 940
was obtained from Loba chemicals Mumbai. Dialysis mem-
brane was procured from Hi media, Mumbai. All other chem-
icals used were of analytical grade and were used without any
further chemical modiﬁcation.
2.2. Preparation of emulgel
Different formulations were prepared using varying amount of
gelling agent and penetration enhancers. The method only dif-
fered in process of making gel in different formulation. The
preparation of emulsion was same in all the formulations.
The gel phase in the formulations was prepared by dispersing
Carbopol 940 in puriﬁed water with constant stirring at a mod-
erate speed using mechanical shaker, then the pH was adjusted
to 6–6.5 using tri ethanol amine (TEA). The oil phase of the
emulsion was prepared by dissolving span 20 in light liquid
parafﬁn while the aqueous phase was prepared by dissolvingTable 1 Composition of different formulation batches (%w/w).
Ingredient F1 F2 F3 F4
Mefenamic acid 1 1 1 1
Carbapol 940 1 1 1 1
Liquid paraﬃn 7.5 7.5 7.5 7.5
Tween 20 0.5 0.5 0.5 0.5
Span 20 1 1 1 1
Propylene glycol 5 5 5 5
Ethanol 2.5 2.5 2.5 2.5
Methyl parabene 0.03 0.03 0.03 0.03
Ethyl parabene 0.01 0.01 0.01 0.01
Clove oil - – 8 10
Mentha oil 4 6 – –
Water q.s q.s q.s q.stween 20 in puriﬁed water. Methyl and propyl parabens were
dissolved in propylene glycol whereas mefenamic acid was dis-
solved in ethanol, and both solutions were mixed with the
aqueous phase. Clove oil and mentha oil were mixed in oil
phase. Both the oily and aqueous phases were separately
heated to 70–80 C, then the oily phase was added to the aque-
ous phase with continuous stirring until it got cooled to room
temperature. The obtained emulsion was mixed with the gel in
1:1 ratio with gentle stirring to obtain the emulgel (Jain et al.,
2011). The composition of different formulations has been dis-
cussed in Table 1.
2.3. Evaluation of emulgel
2.3.1. Physical examination
The prepared emulgel formulations were inspected visually for
their color, appearance and consistency (Kasliwal et al., 2008).
2.4. Rheological study
The viscosity of the formulated batches was determined using
a cone and plate viscometer with spindle 7 (Brookﬁeld Engi-
neering Laboratories). The assembly was connected to a ther-
mostatically controlled circulating water bath maintained at
25 C. The formulation whose viscosity was to be determined
was added to a beaker covered with thermostatic jacket. Spin-
dle was allowed to move freely into the emulgel and the read-
ing was noted (Bonacucina et al., 2009).
2.5. Spreading coefﬁcient
Spreading coefﬁcient was determined by apparatus suggested
by Mutimer. It consists of a wooden block, which is attached
to a pulley at one end. Spreading coefﬁcient was measured on
the basis of ‘Slip’ and ‘Drag’ characteristics of emulgels. A
ground glass slide was ﬁxed on the wooden block. An excess
of emulgel (about 2 g) under study was placed on this ground
slide. The emulgel preparation was then sandwiched between
this slide and second glass slide having same dimension as
that of the ﬁxed ground slide. The second glass slide is pro-
vided with the hook. Weight of 500 mg was placed on the
top of the two slides for 5 min to expel air and to provide
a uniform ﬁlm of the emulgel between the two slides. Mea-
sured quantity of weight was placed in the pan attached to
the pulley with the help of hook. The time (in s) required
by the top slide to cover a distance of 5 cm was noted. A
shorter interval indicates better spreading coefﬁcient (Gupta
and Gaud, 2005).
2.6. Skin irritation test (patch test)
A set of 8 rats was used in the study. The emulgel was applied
on the properly shaven skin of rat. Undesirable skin changes,
i.e., change in color, change in skin morphology were checked
for a period of 24 h (Murty and Hiremath, 2001).
2.7. Bioadhesive strength measurement
The modiﬁed method was used for the measurement of bioad-
hesive strength. The apparatus consist of two arm balance.
Both the ends are tied to glass plates using strings. One side
contains two glass plates. Other side contains single glass plate
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adding extra weight on the left hand pan. The balance was
kept in this position for 5 min.
Accurately weighed 1 g of emulgel was placed between
these two slides containing hairless fresh rat skin pieces, and
extra weight from the left pan was removed to sandwich the
two pieces of glass and some pressure was applied to remove
the presence of air. The balance was kept in this position for
5 min. Weight was added slowly at 200 mg/min to the left hand
pan until the two glass slides got detached from each other.
The weight (gram force) required to detach the emulgel from
the glass surface gave the measure of bioadhesive strength
(Choi et al., 2003). The bioadhesive strength is calculated by
using following:
Biodhesive strength ¼Weight required ðin gÞ=Area ðcm2Þ:Table 2 Physical parameters of formulation batches.
Formulation Color Homogeneity Consistency Phase
separation
F1 White Excellent Excellent None
F2 White Excellent Excellent None
F3 Pale yellow Excellent Excellent None
F4 Yellow Excellent Excellent None2.8. In vitro release studies
The in vitro drug release studies were carried out using a mod-
iﬁed Franz diffusion (FD) cell. The formulation was applied
on dialysis membrane which was placed between donor and
receptor compartment of the FD cell. Phosphate buffer pH
7.4 was used as a dissolution media. The temperature of the
cell was maintained at 37 C by circulating water jacket. This
whole assembly was kept on a magnetic stirrer and the solution
was stirred continuously using a magnetic bead. A similar
blank set was run simultaneously as a control. Sample (5 ml)
was withdrawn at suitable time intervals and replaced with
equal amounts of fresh dissolution media. Samples were ana-
lyzed spectrophotometrically at 285 nm and the cumulative
% drug release was calculated. The difference between the
readings of drug release and control was used as the actual
reading in each case (Kakkar and Gupta, 1992).
2.9. Ex vivo drug release study
The ex vivo drug release study of selected formulations (F2
and F4) was carried out in a modiﬁed Franz diffusion cell,
using wistar male rat skin. A section of skin was cut and placed
in the space between the donor and receptor compartment of
the FD cell, keeping the dorsal side upward. Phosphate buffer
pH 7.4 was used as dissolution media. The temperature of the
cell was maintained constant at 32 C by circulating water
jacket. This whole assembly was kept on a magnetic stirrer
and the solution was stirred continuously using a magnetic
bead. A similar blank set was run simultaneously. The samples
were withdrawn at suitable time intervals and replaced with
equal amounts of fresh dissolution media (Schreier and Bouw-
stra, 1985). Samples were analyzed spectrophotometrically at
285 nm.
2.10. In vivo anti-inﬂammatory activity
2.10.1. Experimental design
Edema was induced on the left hind paw of the rats by subpl-
antar injection of 1% (w/v) carrageenan. Formulations, i.e.,
F2, F4 and standard (diclofenac sodium gel) were applied
30 min before carrageenan administration. The paw volume
was measured at intervals of 30, 60, 90, 120 min by mercury
displacement method using plethysmometer (Crunkhorn and
Mencock, 1971). Group 1 (Control group): Carrageenan (1%) was adminis-
tered in the plantar surface of rat.
 Group 2 (Standard group): Topical marketed diclofenac
gel + Carrageenan.
 Group 3 (Test): Formulations F2 and F4 + Carrageenan.
The % inhibition of paw edema in drug treated group was
compared with carrageenan control group and calculated
according to the formula:
% Inhibition of drug ¼ Vc  Vt=Vc  100
where Vc is the inﬂammatory increase in paw volume con-
trol group and Vt the inﬂammatory increase in paw volume in
(drug + carrageenan) treated animals.
2.11. In vivo analgesic activity
The analgesic activity was carried out using hot plate method.
Following groups were made and latency period in which rat
responded to hot plate was calculated (Junping et al., 2005).
 Group 1 (Control Group): No topical treatment was given
and latency period was calculated.
 Group 2 (Standard Group): The rats were treated with dic-
lofenac gel and its latency period was calculated.
 Group 3 (Test Group): The rats were treated with test for-
mulations, i.e., F2 and F4 and latency period was calculated.
2.12. Stability studies
The prepared emulgels were packed in aluminum collapsible
tubes (5 g) and subjected to stability studies at 5 C, 25 C/
60% RH, 30 C/65% RH, and 40 C/75% RH for a period
of 3 months. Samples were withdrawn at 15-day time intervals
and evaluated for physical appearance, pH, rheological prop-
erties and drug content (Harmonized Tripartite Guidelines,
2003).3. Results and discussion
3.1. Physical appearance
Emulgel formulations were yellowish white viscous creamy
preparation with a smooth homogeneous texture and glossy
appearance. Results have been discussed in Table 2.
3.2. .Spreading coefﬁcient
The spreading coefﬁcient of various emulgel formulations are
given below in Fig. 1.
Figure 4 In vitro cumulative % drug release of formulation F1–
F4.




F1 F2 F3 F4
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
5 08.90 ± 0.010 11.02 ± 8.65 11.82 ± 6.83 14.55 ± 30.44
10 12.20 ± 0.05 14.92 ± 9.64 14.54 ± 13.30 15.76 ± 10.20
15 09.78 ± 1.30 20.43 ± 6.83 10.44 ± 10.2 18.24 ± 15.70
20 24.70 ± 2.25 29.04 ± 10.2 32.74 ± 0.03 25.75 ± 0.020
30 38.10 ± 31.70 40.95 ± 24.9 42.14 ± 0.38 41.84 ± 0.03
60 44.60 ± 31.70 42.56 ± 3.10 41.64 ± 7.55 48.04 ± 3.10
120 50.00 ± 7.55 47.37 ± 2.90 47.44 ± 3.10 53.74 ± 13.30
240 52.23 ± 2.85 53.48 ± 2.31 51.25 ± 0.49 56.01 ± 2.30
Figure 1 Spreading coefﬁcient of the formulation F1–F4
(mean ± SD).
Figure 3 Bioadhesive strength of formulations F1–F4 (mean ±
SD).
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The tests were performed at 100 rpm for 10 min. Results are
given in Fig. 2.
3.4. Skin Irritation test
No allergic symptoms like inﬂammation, redness, irritation ap-
peared on rats up to 24 h.
3.5. Biodhesive strength measurement
The bioadhesive strength of various emulgel formulations have
been shown below in Fig. 3.
3.6. In vitro release study
The study showed the release of the drugs from its emulsiﬁed
gel formulation can be ranked in the following descending or-
der: F4 > F1 > F2 > F3 where the amounts of the drug re-
lease of the drug released after 240 min were 56.01%,
53.48%, 52.23%, 51.21%, respectively (Fig. 4, Table 3).
3.7. Ex vivo release study
This study was carried out only on two best optimized formu-
lations. The study showed the release of the drugs from its
emulsiﬁed gel formulation F2 and F4 were 55.47% and
56.60%, respectively in 240 min. The results are show in Fig. 5.Figure 2 Viscosity of the formulations F1–F4 (mean ± SD).3.8. Anti-inﬂammatory activity
The anti-inﬂammatory action of formulation F2 and F4 was
calculated and it was compared with diclofenac sodium (mar-
keted preparation). The % inhibition of diclofenac sodium, F2
and F4 were found to be 65.71%, 54.28% and 55.72%, respec-
tively. This showed that the formulations were as effective as
marketed formulation.
3.9. Analgesic activity
The formulations showed hike in lapse time. They were com-
pared with diclofenac sodium gel (marketed preparation).
Figure 5 Ex vivo cumulative % release of formulations F2 and
F4.
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found to be 6.8 s, 5 s and 5.1 s.
3.10. Stability study
All the prepared emulgel formulations were found to be stable
upon storage for 3 months, no change was observed in their
physical appearance, pH, rheological properties and drug
content.
4. Conclusion
In the coming years, topical drug delivery will be used exten-
sively to impart better patient compliance. Since emulgel is
helpful in enhancing spreadability, adhesion, viscosity and
extrusion, this novel drug delivery become popular. Moreover,
they will become a solution for loading hydrophobic drugs in
water soluble gel bases for the long term stability.
Similarly in the study, topical emulgels of mefenamic acid
were formulated and subjected to physicochemical studies i.e.
rheological studies, spreading coefﬁcient studies and bioadhe-
sion strength, in vitro release studies and ex vivo release studies
through rat skin. In vitro release of the tests formulations were
performed to determine drug release from emulgel rate and
duration of drug release. From the in vitro studies, formula-
tion F4 showed maximum release of 56.23% in 240 min. Ex
vivo drug release was also performed in which formulation
F4 showed best release of 56% in 240 min. Carrageenan
induced paw edema and hot plate tests revealed anti-inﬂamma-
tory and analgesic activity. The formulations F2 and F4 were
comparable with marketed diclofenac topical gel.
So mefenamic acid emulgel can be used as an anti-
inﬂammatory analgesic agent for topical drug delivery.References
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